The pharmaceutical industry is evolving rapidly and embracing Pharma 4.0™, including AI, machine learning, the Internet of Things, process analytical technology, blockchain and big data analytics. Pharma 4.0 encompasses a holistic transformation of culture, capabilities and connectivity but requires companies to overcome key challenges including evolving regulations, changing technologies, cybersecurity workforce skill gaps, legacy systems and a lack of data governance.
To help address these challenges, ISPE released the ISPE Good Practice Guide: Pharma 4.0™ – Holistic Digital Enablement, which offers flexible, best-practice-driven strategies that can be adapted to an organization’s unique culture, technological landscape and digital maturity level. ISPE experts recently met to discuss their thoughts on the Guide and how companies can realize the full benefits of Pharma 4.0.
Where is the industry now, as far as the transformation timeline?
“While it would be ideal to say that all companies are well underway in their digital transformation journey, that simply isn’t the case,” said Yvonne Duckworth, co-chair for the ISPE Pharma 4.0™ Community of Practice. “I would say larger pharmaceutical organizations are generally further along and actively progressing toward digital transformation. However, many small and mid-sized companies are still the early stages – or have yet to begin.
At a recent conference that I attended, I spoke with three smaller pharmaceutical companies that had never conducted a digital maturity assessment. This is not uncommon. Many organizations are just starting out, and the Guide provides an excellent framework to help them initiate their journey and identify priority areas for advancement.”
How are organizations dealing with their legacy systems?
Organizations are actively evaluating how best to manage their legacy systems,” Duckworth said. “Replacing all existing equipment with new technologies is neither practical nor cost‑effective, which highlights the need for a deliberate and phased transition strategy. Companies must consider thoughtful, well‑informed approaches to address these complexities.
The Guide’s section on information systems is particularly valuable because it provides actionable insights for shop‑floor personnel, engineering teams and IT professionals—groups that encounter these challenges daily.”
What is a common mistake organizations make related to digitization?
Nuha Al-Hafez, Sr. Director, Quality and Compliance for FUJIFILM Biotechnologies, stressed that data governance is essential. “Looking at FDA warning letters and Form 483s, one of the biggest insights is about lack of data governance. A number of companies are focusing on data integrity but not data governance. Data integrity is the number one pillar of data governance but it is not the only pillar you need to look at and need to comply with.”
“I would recommend this Guide to not only leadership but also the team working on data governance and the compliance team to give them guidance about establishing data governance.
We need it at the leadership level, and we need to build these competencies at the shop floor and at the mid-management level as well.”
Other than the Guide, how can organizations ensure they have a broad perspective on Pharma 4.0?
Al-Hafez noted that while the FDA has said CFR Part 11 on electronic records is dated, companies should not wait for updates before modernizing their procedures. The agency is expecting companies to step up, adapt and engage with regulators now, and the Good Practice Guide can help organizations ensure they are doing digital transformation the right way.